acetylcarnitine has been researched along with Parkinson Disease in 8 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism." | 2.50 | Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "Parkinson's disease is accompanied by nonmotor symptoms including cognitive impairment, which precede the onset of motor symptoms in patients and are regulated by dopamine (DA) receptors and the mesocorticolimbic pathway." | 1.48 | Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. ( Mishra, A; Shukla, R; Shukla, S; Singh, S; Srivastava, N, 2018) |
| "Two groups of 10 patients with Parkinson's disease received doses of either 1g acetyl-L-carnitine (ALC) per day for seven days or 2g." | 1.28 | Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease. ( Brancasi, B; D'Ursi, R; Genco, S; Martino, R; Miccoli, A; Prudenzano, A; Puca, FM; Savarese, M; Scarcia, R; Specchio, LM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villa, RF | 1 |
| Ferrari, F | 1 |
| Gorini, A | 1 |
| Phillipson, OT | 1 |
| Singh, S | 2 |
| Mishra, A | 2 |
| Shukla, S | 2 |
| Srivastava, N | 1 |
| Shukla, R | 1 |
| Zhang, H | 1 |
| Jia, H | 1 |
| Liu, J | 2 |
| Ao, N | 1 |
| Yan, B | 1 |
| Shen, W | 1 |
| Wang, X | 1 |
| Li, X | 1 |
| Luo, C | 1 |
| Zaitone, SA | 1 |
| Abo-Elmatty, DM | 1 |
| Shaalan, AA | 1 |
| Beal, MF | 1 |
| Puca, FM | 1 |
| Genco, S | 1 |
| Specchio, LM | 1 |
| Brancasi, B | 1 |
| D'Ursi, R | 1 |
| Prudenzano, A | 1 |
| Miccoli, A | 1 |
| Scarcia, R | 1 |
| Martino, R | 1 |
| Savarese, M | 1 |
2 reviews available for acetylcarnitine and Parkinson Disease
| Article | Year |
|---|---|
Management of the aging risk factor for Parkinson's disease.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb | 2014 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
6 other studies available for acetylcarnitine and Parkinson Disease
| Article | Year |
|---|---|
ATP-ases of synaptic plasma membranes in striatum: enzymatic systems for synapses functionality by in vivo administration of L-acetylcarnitine in relation to Parkinson's Disease.
Topics: Acetylcarnitine; Acetylcholine; Acetylcholinesterase; Animals; Ca(2+) Mg(2+)-ATPase; Calcium-Transpo | 2013 |
ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Antioxidants; Ataxia; Axons; Behavior, Animal; Brain; Cell Nucleus; Diseas | 2016 |
Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Cell Line; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glio | 2018 |
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease.
Topics: Acetylcarnitine; alpha-Synuclein; Antioxidants; Drug Synergism; Humans; Mitochondria; Oxidation-Redu | 2010 |
Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Antioxidants; Dietary Supplements; Dopamine; Dopam | 2012 |
Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.
Topics: Acetylcarnitine; Adult; Aged; Carnitine; Electroencephalography; Electromyography; Female; Humans; M | 1990 |